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TO THE EDITOR
The aryl hydrocarbon receptor (AhR)
is a ligand-activated transcription factor
that mediates the toxicity of 2,3,7,
8-tetrachlorodibenzo-p-dioxin (TCDD),
polycyclic aromatic hydrocarbons, and
related environmental contaminants
(Abel and Haarmann-Stemmann, 2010).
The unligated AhR is trapped in a
cytosolic multiprotein complex, which
rapidly dissociates upon ligand binding.
Subsequently, the AhR shuttles into the
nucleus, dimerizes with ARNT, and
binds to xenobiotic-responsive elements
(XREs) in the promoter of target genes,
e.g., encoding cytochrome P450 (CYP) 1
monooxygenases, to enforce transcrip-
tion (Abel and Haarmann-Stemmann,
2010). Furthermore, AhR-triggered acti-
vation of c-src tyrosine kinase stimulates
EGFR and downstream mitogen-acti-
vated protein kinase signaling, resulting
in the induction of XRE-independent
genes, such as cyclooxygenase-2 (COX-2;
Abel and Haarmann-Stemmann, 2010).
We have previously shown that the
AhR in keratinocytes is not only activa-
ted by anthropogenic chemicals but also
by UVB irradiation, which leads to the
intracellular formation of the tryptophan
photoproduct and high-affinity AhR
ligand 6-formylindolo[3,2-b]carbazole
(FICZ; Rannug et al., 1995; Fritsche
et al., 2007). Indeed, UVB exposure en-
hances AhR/XRE binding (Supplemen-
tary Figure 1 online) and accompanied
CYP1A1/1B1 expression (Katiyar et al.,
2000), as well as XRE-independent
COX-2 expression (Fritsche et al.,
2007).
Because (i) overexpression of a con-
stitutively active AhR causes inflamma-
tory skin lesions (Tauchi et al., 2005),
(ii) an increase in CYP activity leads to
reactive oxygen species formation
(Puntarulo and Cederbaum, 1998), (iii)
CYP1 enzymes are critical for chemical-
induced skin carcinogenesis (Shimizu
et al., 2000), and (iv) COX-2 is
involved in UV-induced inflammation
and carcinogenesis (Elmets et al., 2010),
it was postulated that a transient inhi-
bition of AhR may protect human skin
against the detrimental effects of UVB
irradiation (Agostinis et al., 2007;
Haarmann-Stemmann et al., 2012).
Moreover, we have shown that the
expression of matrix metalloproteinase-
1 (MMP-1), which is critically involved
in extrinsic skin aging, is upregulated in
an AhR-dependent manner in tobacco
smoke extract–exposed keratinocytes
(Ono et al., 2013). Therefore, we deci-
ded to develop an AHR antagonist that
is suitable for topical UV-protection.
We screened a library of compounds
that possess the structural prerequisites to
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interact with AhR and identified E/Z-2-
benzylidene-5,6-dimethoxy-3,3-dimethyl-
indan-1-one (BDDI; Figure 1a) as the
most promising candidate.
In concentrations from 0.33 to 33mM,
BDDI did not negatively affect cell via-
bility or cause cytotoxicity in normal
human epidermal keratinocytes (NHEKs;
Figure 1b; for description of methods
see Supplementary Material online). It is
noteworthy that exposure to higher
concentrations of BDDI enhanced cell
viability (Figure 1b) without increasing
the proliferation rate (data not shown).
Exposure of NHEKs to 0.33 to 33mM
BDDI or 10mM of the specific AhR inhi-
bitor 30-methoxy-40-nitroflavone (MNF;
Lu et al., 1995) resulted in a concentra-
tion-dependent decrease of basal CYP1A1
expression (Figure 1c). AhR activation by
10nM FICZ or 250 nM benzo(a)pyrene
[B(a)P] resulted in 12- to 14-fold induction
of CYP1A1 transcription after 4h, where-
as irradiation with 100 Jm 2 UVB led to
a fourfold increase in CYP1A1 expression
after 8 hours (Figure 1c). Pretreatment
with 10mM MNF or 33mM BDDI signifi-
cantly attenuated CYP1A1 induction.
Interestingly, a dose of 3.3mM BDDI
was sufficient to repress UVB- and
FICZ-stimulated, but not B(a)P-induced,
CYP1A1 expression, which was probably
due to the different half-lives of the
inducing agents (Figure 1c). To confirm
the inhibitory effect of BDDI on CYP1A1,
we treated NHEKs for 24h with 250nM
B(a)P alone or in combination with
BDDI and measured CYP1A-mediated
7-O-ethoxyresorufin-deethylase (EROD)
activities. A 1 hour pretreatment with
0.33 to 33mM BDDI resulted in a dose-
dependent decline of B(a)P-induced
EROD activity (Figure 1d), thereby con-
firming the AhR antagonistic properties
of BDDI. Importantly, BDDI only tran-
siently represses AhR function. Whereas
a BDDI pretreatment for 1 hour attenu-
ated UVB-mediated CYP1A1 induction
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Figure 1. Characterization of antagonistic capacities of E/Z-2-benzylidene-5,6-dimethoxy-3,3-dimethylindan-1-one (BDDI) in normal human epidermal
keratinocytes (NHEKs). (a) Chemical structure of BDDI. (b) Effect of BDDI on cell viability (CellTiter Blue; CTB) and cytotoxicity (lactate dehydrogenase; LDH).
The black line marks the respective control level. (c) Effect of BDDI on B(a)P (250 nM for 4 hours)-, 6-formylindolo[3,2-b]carbazole (FICZ; 100 nM for 4 hours)-, and
UVB (100 J m 2 for 8 hours)-induced CYP1A1 mRNA expression (quantitative reverse transcription-PCR data). (d) Effect of BDDI on 7-O-ethoxyresorufin-
deethylase (EROD) activity induced by 24 hours B(a)P shown in activity as pmol min 1mg 1. (e) Transient effect of BDDI pretreatment (1 and 24 hours)
on CYP1A1 mRNA expression induced by 100 J m2 UVB. (f) NHEKs were irradiated with 100 J m 2 UVB and directly after irradiation treated with 3.3 and
33mM BDDI. After 8 hours, RNA was isolated, and CYP1A1 transcription was analyzed. Each graph represents mean±SEM of three independent experiments;
*Po0.05 versus medium/DMSO control; #Po0.05 versus treatment (B(a)P, FICZ, or UVB, respectively).
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in NHEKs, a pretreatment for 24 hours
was not effective (Figure 1e). BDDI
treatment of NHEKs directly after irra-
diation also decreased UVB-mediated
CYP1A1 induction, providing evidence
that BDDI does not act as a UVB-filter
(Figure 1f).
To elucidate the mode of action of
BDDI, we performed an electrophoretic
mobility shift assay (EMSA) that is well
established to detect a direct binding of
AhR/ARNT to a XRE consensus oligo-
nucleotide (Denison et al., 1988; Vogel
et al., 2004). Upon exposure of human
HaCaT keratinocytes to 10 nM TCDD or
100 nM FICZ, we observed a strong
binding of the AhR/ARNT complex to
its DNA target motif (Figure 2a). Co-
exposure of HaCaT cells to 3.3mM BDDI
or 10mM MNF clearly blocked TCDD-
and FICZ-triggered AhR/XRE binding
(Figure 2a), providing evidence that
BDDI acts as a true competitive AhR
antagonist.
To investigate whether BDDI is suita-
ble for UV-protection of human skin, we
treated defined skin areas of 10 healthy
volunteers once daily on 4 consecutive
days with a formulation containing
0.5% BDDI or a placebo formulation
(Figure 2b). On day 4, 2 hours after the
application of the substances, volunteers
were irradiated with 1.5 MED (minimal
erythema dose) UVB, and 24 hours later
skin biopsies were taken. Quantitative
expression analyses revealed a signifi-
cantly increased expression of CYP1A1,
COX-2, and MMP-1 in UVB-irradiated
compared with sham-irradiated skin.
Topical application of BDDI, but not
the placebo formulation, significantly
reduced the UVB-induced expression
of all these genes, indicating that BDDI
penetrates human skin and blocks AhR-
dependent signaling. This experiment
also revealed that the AhR is activated
upon UVB irradiation in human skin
in vivo. Importantly, the erythema res-
ponse of the volunteers was not signifi-
cantly affected during the study.
As CYP1A1, COX-2, and MMP-1
are critically involved in cutaneous
inflammatory diseases, skin cancer,
and skin aging, we propose that the
topical application of this chemical inhi-
bitor presents a promising strategy to
protect human skin against UVB-
induced damage. In contrast to MNF
(structural safety alert), BDDI has the
clinical advantage of being suitable for
dermal applications in humans. Our
in vitro data further indicate that BDDI
may protect against the adverse effects
of polycyclic aromatic hydrocarbons,
which are frequently found on airborne
particulate matter (Vierkotter et al., 2010).
Finally, BDDI may serve as a tool to
study the involvement of AhR signaling in
human skin (patho)physiology.
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Figure 2. BDDI disturbs XRE binding of aryl hydrocarbon receptor (AhR)/ARNT and represses
UVB-induced gene expression in a human in vivo study. (a) HaCaT keratinocytes were treated with
10 nM 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 100 nM 6-formylindolo[3,2-b]carbazole (FICZ),
10mM 30-methoxy-40-nitroflavone (MNF), and/or 3.3mM BDDI for 90 minutes before isolation of nuclear
extracts and were hybridized with a xenobiotic-responsive element (XRE) consensus oligonucleotide.
A representative electrophoretic mobility shift assay of three independent experiments is shown.
(b) Volunteers were pretreated with 0.5% BDDI or placebo for 4 days every day followed by UVB
irradiation (1.5 minimal erythema dose, MED) on day 4. Twenty-four hours after irradiation, 4-mm skin
biopsies were taken, RNA was isolated and reverse transcribed, and mRNA expression of CYP1A1,
cyclooxygenase-2, and matrix metalloproteinase-1 was measured. Gene expression in sham-irradiated,
untreated control skin were arbitrarily set as 1; n¼10, mean±SEM, *Po0.001 versus unirradiated control,
#Po0.001 versus UVB (1.5 MED).
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TO THE EDITOR
Exposure to solar UVR continues to be a
major contributing factor in the increase
in the incidence of skin cancer. Muta-
genic photoproducts formed in the DNA
of UV-exposed cells, specifically due to
absorption of radiation in the UVB range
of 280–320 nm, include cyclobutane
pyrimidine dimers (CPDs) and pyrimi-
dine (6–4) photoproducts (Rastogi et al.,
2010). The CPDs are the major
contributors to mutations in mammals,
as they are repaired less quickly than
(6–4) photoproducts. Recent studies
suggest that some of the existing UV-
filtering agents can form harmful photo-
degradation products (Hanson et al.,
2006; Mosley et al., 2007; Burnett and
Wang, 2011). Therefore, there is a pres-
sing need for new strategies of photo-
protection to reduce the detrimental
effects of UVR. To this end, we
adopted a bio-mimetic approach for
photoprotection using acyclothymidine
dinucleosides (aTds).
It has been shown that topical applica-
tion of thymidine dinucleotides resulted
in DNA photoprotection (Goukassian
et al., 2004, 2012; Arad et al., 2008).
The aTds eliminate the complex and
unstable phosphate-linked diribofura-
nosyl moieties in oligonucleotides and
are inexpensive to prepare (Figure 1a). In
addition, they retain the ability to offer
photoprotection by mimicking the vul-
nerable adjacent thymidine sequences
present in DNA molecules.
We have recently reported that aTd
protects plasmid and cellular DNA
(in vitro) from UVR while undergoing a
photocatalyzed [2þ2] cycloaddition to
form UV non-cytotoxic cyclobutane
dimers (Raza et al., 2013). These
non-cytotoxic mimetics of naturally
occurring DNA dithymidine sequences
have UV adsorption spectra comparable
to native DNA thymidine and are
similar to the naturally occurring
excised DNA thymine dimers. We
have now examined the efficacy of
aTd to reduce the incidence of cellular
DNA thymine dimer formation after
exposure to UVB irradiation in three
separate experiments using the SKH1-E
hairless mouse model (Crl:SKH1-Hr hr
strain code 477, Charles River Labora-
tories International, Wilmington, MA)
and human abdominal skin explants.
For all studies, detailed methodology
can be found in accompanying Supple-
mentary Information online.
ACUTE UVB EXPOSURE
Dorsal skin of immunocompetent, hair-
less SKH1-E mice and humanAccepted article preview online 12 August 2013; published online 19 September 2013
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